Switzerland-based global healthcare company Novartis (NVS) is gaining momentum this year, thanks to solid pipeline execution, new regulatory wins, high-value license transactions, capital return to shareholders, and positive market sentiment. Novartis stock has surged 36.3% year-to-date, outperforming the broader market. Following Sandoz’s (SDZNY) 2023 spinoff, Novartis is a pure-play innovative medicines firm focused on high-value therapeutic areas. More News from Barchart The company is scheduled to r ...

“European and other rich countries consistently underspend on innovative medicines,“ writes the former chair of America’s Council of Economic Advisers in a guest essay. This shifts “the burden of paying for medical progress onto the Americans” https://t.co/s8PcFIUhl5 ...

The former chair of America’s Council of Economic Advisers wants NATO-style spending targets for innovative medicines https://t.co/9DKnOSIinlIllustration: Dan Williams https://t.co/8KqA2PQuKf ...

Core Viewpoint - Amgen Inc. is experiencing strong financial momentum and growth across its portfolio and pipeline, driven by increasing global demand for its innovative medicines [3]. Financial Performance - In the first quarter, Amgen's revenue increased by 9% year-over-year, primarily due to a 14% growth in volume [4]. - The growth was broad-based, with 14 products achieving double-digit growth [4]. Leadership and Expertise - The conference featured key executives including Peter Griffith (CFO), Dr. Jay Bradner (EVP of R&D), and Justin Claeys (VP of Investor Relations), highlighting their extensive experience in the industry [1][2].